FDA Approves Eylea For Treatment Of Diabetic Macular Edema

Home
Cataract
Cornea
Glaucoma
Refractive
Retina
Practice Management

Thursday, July 31, 2014

Comments

Ocular Surgery News

The U.S. Food and Drug Administration has approved Eylea for treatment of diabetic macular edema, according to a Regeneron Pharmaceuticals press release.

Full Abstract

The steroid that is least likely to cause a posterior subcapsular cataract is:
1. dexamethsone
2. prednisolone
3. loteprednol
4. triamcinolone
Check The Answer

SPECTRALIS Diagnostic Imaging Platform
A modular and upgradeable ophthalmic ... view product
Smartphone-Based Retinal Screening System
D-EYE, The Modern Day Digital ... view product

View all Featured Products »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.

Like us
on Facebook Follow us
on Twitter

OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.

Learn more about writing for us

AdGlare Leaderboard

FDA Approves Eylea For Treatment Of Diabetic Macular Edema

Comments

Quick Quiz

The steroid that is least likely to cause a posterior subcapsular cataract is:

AdGlare RMR Ad

Featured Products

SPECTRALIS Diagnostic Imaging Platform

Smartphone-Based Retinal Screening System

Follow OphthalmologyWeb

AdGlare RMR2

Write for Us